Preclinical research involving mice suggests that very low doses of psilocybin could treat obesity, type 2 diabetes and fatty liver disease through a liver-based mechanism distinct from the compound’s psychedelic properties.
This story first appeared on leafie, view here
Author: Kevin Dinneen
Copyright © 2020 – 2025 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.